ID   SRIK-NKL
AC   CVCL_IP68
DR   Wikidata; Q54955675
RX   PubMed=15927673;
CC   Population: Caucasian.
CC   Doubling time: 36-48 hours (PubMed=15927673).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: NK T-cell; CL=CL_0000814.
ST   Source(s): PubMed=15927673
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 11,13
ST   D16S539: 13
ST   D5S818: 11
ST   D7S820: 8,9
ST   TH01: 7,9.3
ST   TPOX: 11
ST   vWA: 15,17
DI   NCIt; C82217; Natural killer cell lymphoblastic leukemia/lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   16-17Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 30-01-24; Version: 5
//
RX   PubMed=15927673; DOI=10.1016/j.leukres.2004.12.017;
RA   Srivastava, Bejai Inder Sahai
RA   Srivastava, Maya D.
RT   "Establishment and characterization of SRIK-NKL: a novel CD8+ natural
RT   killer/T cell line derived from a patient with leukemic phase of acute
RT   lymphoblastic lymphoma.";
RL   Leuk. Res. 29:771-783(2005).
//